CMR survey in Thalassemia Intermedia patients

CMR survey in Thalassemia Intermedia patients

Results One-hundred and eighty-eight (74.6%) patients showed no MIO in any segment, 56 (22%) had an heterogeneous distribution (52 with global heart T2*≥20 ms), and 8 (0.3%) showed an homogeneous MIO. Left ventricular (LV) and right ventricular (RV) dilatations were present in 113 (45%) and in 49 (19%) patients, respectively. LV dysfunction was present in the 18.0% of the cases while RV dysfunc...

Pulmonary thromboembolism in thalassemia intermedia patients.

hybrid (myeloid-erythroid) blasts has been proposed to be a characteristic bone marrow feature in EL, but has not as yet been emphasized as a morphologic feature of the disease.4 Erythroblasts with peripheral chromatin condensation are sufficiently characteristic for a provisional diagnosis of B 19 infection to be made on the histology5 and rare erythroblasts with this morphologic feature could...

Echocardiographic Evaluation of Thalassemia Intermedia Patients in

Thalassemia intermedia.

Thalassemia intermedia is a clinical definition applied to patients whose clinical phenotype is milder than that of thalassemia major. Criteria used to define thalassemia intermedia including age at presentation, hemoglobin or fetal hemoglobin levels and transfusion independence, are unsatisfactory. The possibility of typing the molecular defect allows a retrospective analysis of patients and o...

Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea

Hydroxyurea (HU) has been successfully used in patients with β-thalassemia intermedia (β-TI). We aimed to evaluate the effect of the long-term use of HU on thyroid function in patients with β-TI. Seventy-five patients with β-TI aged≥11 years and taking HU were randomly selected during 2010 in southern Iran. Thirty-one patients with β-TI without HU were considered as a control group. Serum level...